The effect of race on survival after local therapy in metastatic prostate cancer patients

Elio Mazzone, MD1,2; Marco Bandini, MD1,2; Felix Preisser, MD2,3; Sebastiano Nazzani, MD2; Zhe Tian, MD2; Firas Abdollah, MD4; Denis Soulieres, MD5; Markus Graefen, MD6; Francesco Montorsi, MD1; Shahrokh Shariat, MD3; Fred Saad, MD2; Alberto Briganti, MD2; Pierre I. Karakiewicz, MD2

1Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy; 2Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada; 3Department of Urology, Goethe-Universität Frankfurt am Main, Germany; 4Henry Ford Health System, Detroit, MI, United States; 5Division of Medical Oncology/Hematology Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada; 6Martini-Clinic, Prostate Cancer Centre Hamburg-Eppendorf, Hamburg, Germany; 7Department of Urology, Medical University of Vienna, Vienna, Austria

Cite as: Can Urol Assoc J 2019;13(6):175-81. http://dx.doi.org/10.5489/cuaj.5399

Published online October 15, 2018

See related commentary on page 182

Abstract

Introduction: Local therapy (LT) may offer a survival advantage in highly select, newly diagnosed metastatic prostate cancer (mPCa) patients. However, it is unknown whether the benefits vary in Caucasian vs. African American (AA) patients. Methods: Within the Surveillance Epidemiology and End Results (SEER) database (2004–2014), we focused on Caucasians and AA patients with newly diagnosed mPCa treated with LT: radical prostatectomy (RP) and brachytherapy (RT). Endpoints consisted of cancer-specific mortality (CSM) and overall mortality (OM). Kaplan-Meier analyses and multivariable Cox regression models tested for racial difference in CSM and OM. Results: Between 2004 and 2014, we identified 408 (77.2%) Caucasians and 121 (22.8%) AAs with newly diagnosed mPCa treated with LT: radical prostatectomy (RP) or brachytherapy (RT). According to race, when LT is defined as RP, Caucasian patients had a significantly longer survival vs. AA patients: CSM-free survival 123 vs. 63 months (p=0.004) and OM-free survival 108 vs. 46 months (p=0.002). The CSM and OM benefits were confirmed in multivariable analyses (hazard ratio [HR] 0.56, p=0.01 for CSM; HR 0.60, p=0.01 for OM). However, no differences in CSM or OM were recorded according to race when LT consisted of RT. Conclusions: Our results indicate that race is not associated with difference in survival after LT in mPCa patients. However, when focusing on RP-treated patients, Caucasian race is associated with higher CSM and OM rates relative to AA race. This racial difference does not apply to RT. Our findings should be considered in future prospective trials for the purpose of preplanned stratification according to race.

Introduction

According to several retrospective studies, local therapy (LT) may offer a survival advantage in highly select patients with newly diagnosed metastatic prostate cancer (mPCa).1-10 Nonetheless, the retrospective nature of these studies requires prospective validation. Toward that end, the ongoing g-RAMPP trial11 will provide European data. Similarly, the upcoming SWOG-1802 trial12 and others will provide North American data. To the best of our knowledge, no ongoing study is sufficiently powered to allow preplanned stratification according to race.11,12 Similarly, we are unaware of previous studies that examined the effect of race in retrospective analyses.

In the light of these limitations, our goal was to test the effect of race on cancer-specific mortality (CSM) and overall mortality (OM) in patients treated with LT in the context of newly diagnosed mPCa. Specifically, we hypothesized that the survival benefit of LT may be different according to race (Caucasian vs. African American [AA]), since AA patients may harbour more aggressive prostate cancer characteristics than their Caucasian counterparts.13-21 Moreover, we performed separate analyses for radical prostatectomy (RP) and brachytherapy (RT), based on previously reported differences in the survival benefit according to LT type.6

Methods

Data source and patient selection

The current study relied on the Surveillance Epidemiology and End Results (SEER) database (2004–2014), which samples 26% of the U.S. and approximates the U.S. in terms of demographic composition, as well as of cancer
incidence. In the SEER database, we focused on Caucasian and AA men aged 18 years or older, diagnosed between 2004 and 2014 with histologically confirmed adenocarcinoma of the prostate (International Classification of Disease for Oncology [ICD-O-3] code 8140 site code C61.9). We only considered patients with newly diagnosed mPCa. CSM was defined according to the SEER mortality code. All other deaths were considered as other-cause mortality (OCM). LT types available in SEER database consist of: 1) RP (surgery site codes 50 and 70) with or without external beam radiation therapy (EBRT); or 2) RT (i.e., brachytherapy) with or without EBRT. Brachytherapy was defined as prostate-directed radioactive implants with (“combination of beam with implants or isotopes” according to “Radiation. recode” SEER variable) or without (“radioactive implant” or “radioisotopes according to “Radiation. recode” SEER variable) combined administration of EBRT. EBRT was excluded due to the lack of data regarding target site that allows to distinguish local from extraprostatic treatment. Surgical treatments other than RP were also excluded, as described earlier. These selection criteria yielded 529 patients, who were classified in overall analysis of the effect of LT (RP and RT) according to race. Subsequently, analyses were repeated according to LT type: one set of analyses focused on RP patients and another focused on RT patients.

Statistical analyses and covariates

Kaplan-Meier (KM) and Cox regression model (CRM) were fitted to evaluate CSM and OCM. Race represented the risk variable of interest. In multivariable CRM, adjustment variables consisted of age at diagnosis, prostate-specific antigen (PSA), year of diagnosis, marital status (married, unmarried, unknown), biopsy Gleason score (GS) at diagnosis, clinical stage (cT), clinical lymph node stage (cN0, cNx, cN1), and M1 sub-stage (according to the sixth [2004–2009] and seventh [2010–2014] edition of American Joint Committee on Cancer [AJCC] Cancer Staging Manual [M1a, M1b, M1c]). Medians and ranges were reported for continuously coded variables (age and PSA). The statistical significance of differences in medians and proportions was tested with Kruskal-Wallis and Chi-square tests. All statistical tests were two-sided with a level of significance set at p<0.05. Analyses were performed using the R software (version 3.3.0; http://www.r-project.org/).

Results

General characteristics of the study populations

Overall, we identified 529 men with newly diagnosed mPCa treated with LT from 2004–2014. Of these, 408 (77.2%) were Caucasian and 121 (22.8%) were AA. AA patients had higher median PSA level at diagnosis (18.2 vs. 13.4 ng/ml; p=0.018) and were more frequently unmarried (41.3% vs. 22.5%; p<0.001) than Caucasian patients. Median age at diagnosis was virtually the same between the two groups (65 years for both; p=0.3). According to clinical AJCC M substaging, AAs more frequently harboured M1c stage (26.4% vs. 20.3%; p=0.017). RP was performed in 283 (69.4%) Caucasians and 74 (61.2%) AAs. Similarly, RT was performed in 125 (30.6%) Caucasians and 47 (38.8%) AAs (Table 1).

Survival analyses

In the overall population consisting of RP and RT patients, KM analyses demonstrated CSM-free survival of 123 months for Caucasians vs. 117 months for AAs (p=0.1). Similarly, OM-free survival was 82 months for Caucasians vs. 57 months for AAs (p=0.07) (Fig. 1A). In multivariable analyses, no differences were reported according to race in model that focused on CSM (hazard ratio [HR] 0.71; confidence interval [CI] 0.49–1.03; p=0.07), as well as in the model that focused on OM (HR 0.75; CI 0.54–1.04; p=0.09) (Table 2).

In patients treated with RP, unadjusted KM analyses demonstrated CSM-free survival of 123 months for Caucasians vs. 63 months for AAs (p=0.004), and OM-free survival of 108 months for Caucasians vs. 46 months for AAs (p=0.002) (Fig. 1B). In multivariable Cox regression models, stratification according to Caucasian vs. AA race resulted in HR 0.56 (CI 0.35–0.88; p=0.01). Similarly, in multivariable models predicting OM, stratification according to Caucasian vs. AA race resulted in HR 0.66 (CI 0.40–0.90; p=0.01) (Table 3).

In RT patients, unadjusted KM analyses showed that median CSM-free survival was 82 months for Caucasians and was not reached for AAs (p=0.4). Similarly, OM-free survival was 64 months for Caucasians vs. 68 months for AAs (p=0.4) (Fig. 1C). In multivariable analyses, no differences were identified according to race in models that focused on CSM (HR 1.25; CI 0.62–2.50; p=0.5), as well as in models that focused on OM (HR 1.21; CI 0.67–2.17; p=0.5) (Table 4).

Discussion

In the context of newly diagnosed mPCa, LT has been shown to improve overall survival in several retrospective epidemiological analyses. We hypothesized that AA patients may be associated with lower CSM and OM rates after LT relative to their Caucasian counterparts in the context of mPCa, based on previous evidence suggesting a more aggressive PCA phenotype in AAs. We also postulated that the survival benefit from LT may differ according to LT type: RP vs. RT. To address this hypothesis, we examined the effect of race on CSM and OM in patients with mPCa...
Effect of race on prostate cancer survival

treated with LT that consisted of either RP or RT. Our study yielded several noteworthy findings. First, CSM and OM did not differ between Caucasian and AA patients when LT was defined as either RP and RT. Absence of differences was recorded in both unadjusted and fully adjusted analyses. This finding is consistent with previous studies that examined the effect of LT in the context of mPCa, where LT was defined as either RP and RT.3,6 However, when LT was defined as only RP, OM and CSM analyses showed important survival differences according to race. Specifically, AA patients exhibited worse survival in both CSM and OM analyses. Subsequent analyses that exclusively focused on RT patients failed to demonstrate racial differences in CSM and OM, in both unadjusted and adjusted models. Taken together, these findings illustrate two important points. Our data suggest that racial differences may be associated with survival differences after LT in the context of newly diagnosed mPCa. Our retrospective observations also suggest that a potential survival benefit according to Caucasian race may only apply to LT defined as RP, but not to RT.

These findings have important clinical implications. Until prospective, randomized trials of LT in mPCa context become available with preplanned stratification according to race, our retrospective analysis seems to show a different association between survival and RP according to race. This recommendation needs to be accompanied by a warning about potential flaws originating from retrospective analyses. Our findings also need to be considered, when the type of LT is debated in the context of the mPCa in AA patients.

Table 1. Clinical and pathological characteristics of 529 patients with metastatic prostate cancer treated with local therapy (radical prostatectomy or brachytherapy)

| Variable                     | Overall=529 (100%) | AA=121 (22.8 %) | Caucasian=408 (77.2%) | p   |
|------------------------------|---------------------|------------------|------------------------|-----|
| Local therapy type           |                     |                  |                        |     |
| Brachytherapy                | 172 (32.5)          | 47 (38.8)        | 125 (30.6)             | 0.1 |
| Radical prostatectomy        | 357 (67.5)          | 74 (61.2)        | 283 (69.4)             |     |
| PSA                          |                     |                  |                        |     |
| Median, IQR                  | 14.3 (6.3–58.7)     | 18.2 (7–98)      | 13.4 (6.3–45.2)        | 0.018|
| Age at diagnosis             |                     |                  |                        |     |
| Median, IQR                  | 65 (58–72)          | 65 (57–70)       | 65 (59–72)             | 0.3 |
| Gleason score (biopsy)       |                     |                  |                        |     |
| ≤6                           | 133 (25.1)          | 30 (24.8)        | 103 (25.2)             | 0.5 |
| 7                            | 249 (47.1)          | 51 (42.1)        | 198 (48.5)             |     |
| 8–10                         | 55 (10.4)           | 15 (12.4)        | 40 (9.8)               |     |
| Unknown                      | 92 (17.4)           | 25 (20.7)        | 67 (16.4)              |     |
| Clinical T stage             |                     |                  |                        |     |
| <T2                          | 278 (52.6)          | 67 (55.4)        | 211 (51.7)             | 0.47|
| T2                           | 165 (31.2)          | 39 (32.2)        | 126 (30.9)             |     |
| T3                           | 45 (8.5)            | 3 (2.5)          | 42 (10.3)              |     |
| T4                           | 41 (7.8)            | 12 (9.9)         | 29 (7.1)               |     |
| Clinical N stage             |                     |                  |                        |     |
| N0                           | 225 (42.5)          | 68 (56.2)        | 157 (38.5)             | 0.002|
| N1                           | 76 (14.4)           | 14 (11.6)        | 62 (15.2)              |     |
| NX                           | 228 (43.1)          | 39 (32.2)        | 189 (46.3)             |     |
| AJCC M1 stage                |                     |                  |                        |     |
| M1a                          | 55 (10.4)           | 6 (5)            | 49 (12)                | 0.017|
| M1b                          | 343 (64.8)          | 76 (62.8)        | 267 (65.4)             |     |
| M1c                          | 115 (21.7)          | 32 (26.4)        | 83 (20.3)              |     |
| Unknown                      | 16 (3)              | 7 (5.8)          | 9 (2.2)                |     |
| Marital status               |                     |                  |                        | <0.001|
| Married                      | 358 (67.7)          | 68 (56.2)        | 290 (71.1)             |     |
| Unmarried                    | 142 (26.8)          | 50 (41.3)        | 92 (22.5)              |     |
| Unknown                      | 29 (5.5)            | 3 (2.5)          | 26 (6.4)               |     |
| Year of diagnosis            | 2004                | 39 (7.4)         | 8 (6.6)                | 0.4 |
|                              | 2005                | 42 (7.9)         | 7 (5.8)                |     |
|                              | 2006                | 48 (9.1)         | 15 (12.4)              | 33 (8.1)|
|                              | 2007                | 43 (8.1)         | 12 (9.9)               | 31 (7.6)|
|                              | 2008                | 47 (8.9)         | 7 (5.8)                | 40 (9.8)|
|                              | 2009                | 45 (8.5)         | 13 (10.7)              | 32 (7.8)|
|                              | 2010                | 46 (8.7)         | 11 (9.1)               | 35 (8.6)|
|                              | 2011                | 50 (9.5)         | 12 (9.9)               | 38 (9.3)|
|                              | 2012                | 48 (9.1)         | 15 (12.4)              | 33 (8.1)|
|                              | 2013                | 51 (9.6)         | 9 (7.4)                | 42 (10.3)|
|                              | 2014                | 70 (13.2)        | 12 (9.9)               | 58 (14.2)|

AA: African American; AJCC: American Joint Committee on Cancer; IQR: interquartile range; PSA: prostate-specific antigen.
According to previously reported data, RT did show a survival benefit in retrospective survival analyses focusing on newly diagnosed mPCa. In several of these analyses, RT appeared to provide a benefit that was of lesser magnitude than that derived from RP. Our findings add to the existing evidence and suggest no racial differences in survival when RT is contemplated. In consequence, until randomized, prospective trials examining the effect of LT on survival in mPCa become available, the results of the current analysis may help to better address the use of RP or

Fig. 1. Kaplan-Meier plots: cancer-specific mortality (CSM)-free survival (left column) and overall mortality (OM)-free survival (right column) of 529 Caucasian and African American (AA) patients with newly diagnosed metastatic prostate cancer, stratified according to local therapy type. CI: confidence interval.
Effect of race on prostate cancer survival

Second, regarding the survival benefit observed after RP in the context of mPCa, the advantage recorded in Caucasian patients requires special consideration. All analyses relied on two separate outcomes: CSM and OM. In both analyses, virtually the same results were observed. This observation indicates that RP in newly diagnosed mPCa has a robust beneficial effect in Caucasian patients, when either CSM or OM is examined. Similarities in CSM and OM imply that RP delivered to newly diagnosed metastatic Caucasian patients not only results in more favourable CSM, but also results in more favourable OM (HR 0.56, p=0.01 for CSM; HR 0.6, p=0.01 for OM).

Third, we confirmed the prognostic significance of several established risk variables in newly diagnosed mPCa patients. These variables consisted of biopsy GS, clinical T stage, and PSA. These observations confirm the validity of

### Table 2. Multivariable Cox regression models* predicting CSM and OM in patients with newly diagnosed metastatic prostate cancer treated with local therapy

| Variables          | CSM HR (95% CI) | p   | OM HR (95% CI) | p   |
|--------------------|-----------------|-----|----------------|-----|
| Race               |                 |     |                |     |
| AA                 | REF             |     | REF            |     |
| Caucasian          | 0.71 (0.49–1.03)| p=0.07| 0.75 (0.54–1.04)| p=0.09|
| PSA                |                 |     |                |     |
| <50                | 0.39 (0.22–0.70)| p=0.002| 0.38 (0.23–0.63)| p<0.001|
| 50–98              | REF             |     | REF            |     |
| >98                | 1.10 (0.61–1.99)| p=0.7| 0.93 (0.55–1.57)| p=0.8|
| Gleason score (biopsy) |        |     |                |     |
| ≤6                 | 0.62 (0.26–1.47)| p=0.3| 0.60 (0.30–1.20)| p=0.1|
| 7                  | REF             |     | REF            |     |
| 8–10               | 2.42 (1.50–3.89)| p<0.001| 1.84 (1.24–2.74)| p=0.002|
| Unknown            | 2.91 (1.71–4.94)| p<0.001| 2.33 (1.49–3.84)| p<0.001|
| Clinical T stage   |                 |     |                |     |
| <T2                | REF             |     | REF            |     |
| T2                 | 0.89 (0.61–1.29)| p=0.5| 0.93 (0.67–1.28)| p=0.6|
| T3                 | 0.76 (0.39–1.48)| p=0.4| 0.88 (0.49–1.56)| p=0.6|
| T4                 | 2.46 (1.52–3.97)| p<0.001| 2.19 (1.42–3.40)| p<0.001|
| Clinical N stage   |                 |     |                |     |
| N0/NX              | REF             |     | REF            |     |
| N1                 | 0.62 (0.37–1.05)| p=0.07| 0.70 (0.44–1.11)| p=0.1|
| AJCC M stage       |                 |     |                |     |
| M1a                | REF             |     | REF            |     |
| M1b                | 1.62 (0.37–3.24)| p=0.1| 1.70 (0.94–3.07)| p=0.07|
| M1c                | 2.09 (1.01–4.31)| p=0.045| 1.85 (0.99–3.46)| p=0.05|
| Unknown            | 1.39 (0.47–4.08)| p=0.5| 1.33 (0.51–3.47)| p=0.5|

*Adjusted for age and marital status. AA: African American; AJCC: American Joint Committee on Cancer; CI: confidence interval; CSM: cancer-specific mortality; HR: hazard ratio; OM: overall mortality; PSA: prostate-specific antigen; REF: reference.

### Table 3. Multivariable Cox regression models* predicting CSM and OM in patients with newly diagnosed metastatic prostate cancer treated with radical prostatectomy

| Variables          | CSM HR (95% CI) | p   | OM HR (95% CI) | p   |
|--------------------|-----------------|-----|----------------|-----|
| Race               |                 |     |                |     |
| AA                 | REF             |     | REF            |     |
| Caucasian          | 0.56 (0.35–0.88)| p=0.01| 0.60 (0.40–0.90)| p=0.01|
| PSA                |                 |     |                |     |
| <50                | 0.39 (0.19–0.77)| p=0.007| 0.43 (0.23–0.80)| p=0.007|
| 50–98              | REF             |     | REF            |     |
| >98                | 1.01 (0.50–2.00)| p=0.9| 0.86 (0.46–1.59)| p=0.6|
| Gleason score (biopsy) |        |     |                |     |
| ≤6                 | 0.64 (0.17–2.40)| p=0.5| 0.57 (0.18–1.75)| p=0.1|
| 7                  | REF             |     | REF            |     |
| 8–10               | 3.27 (1.71–6.25)| p<0.001| 2.58 (1.50–4.44)| p<0.001|
| Unknown            | 4.07 (1.98–8.39)| p<0.001| 3.18 (1.50–8.88)| p<0.001|
| Clinical T stage   |                 |     |                |     |
| <T2                | REF             |     | REF            |     |
| T2                 | 1.07 (0.67–1.70)| p=0.7| 1.09 (0.72–1.65)| p=0.056|
| T3                 | 1.26 (0.59–2.69)| p=0.5| 1.12 (0.55–2.26)| p<0.001|
| T4                 | 3.08 (1.72–5.51)| p<0.001| 2.55 (1.49–4.37)| p<0.001|
| Clinical N stage   |                 |     |                |     |
| N0/NX              | REF             |     | REF            |     |
| N1                 | 0.49 (0.27–0.88)| p=0.02| 0.64 (0.23–1.06)| p=0.08|
| AJCC M stage       |                 |     |                |     |
| M1a                | REF             |     | REF            |     |
| M1b                | 1.14 (0.50–2.60)| p=0.7| 1.25 (0.61–2.57)| p=0.5|
| M1c                | 1.07 (0.44–2.60)| p=0.9| 1.01 (0.45–2.21)| p=0.9|
| Unknown            | 0.91 (0.27–3.16)| p=0.9| 0.99 (0.32–3.01)| p=0.9|

*Adjusted for age and marital status. AA: African American; AJCC: American Joint Committee on Cancer; CI: confidence interval; CSM: cancer-specific mortality; HR: hazard ratio; OM: overall mortality; PSA: prostate-specific antigen; REF: reference.
Second, we are not able to assess the exact extent by its retrospective nature, as applicable to previous analyses. To address these limitations, we performed analyses focusing on OM and not only in CSM. Analyses of both endpoints provided virtually the same results. This implies a marginal confounding effect of comorbidities, if any. Fourth, data regarding additional systemic treatments is not available in the SEER registry. Finally, the number of AA patients who benefited from LT was limited. This may have affected the statistical significance of our comparisons. However, the findings regarding racial differences in RP patients were both highly clinically meaningful and highly statistically significant. This implies that sample size did not undermine comparisons of survival according to race in RP patients. Regarding comparisons according to race in RT patients, the sample size was indeed more limited. However, the recorded absolute figures and rates were virtually the same between the two races. This suggests that lack of survival difference in RT patients is unlikely directly related to sample size limitations.

**Conclusion**

Our results indicate that race is not associated with difference in survival after LT in mPCa patients. When focusing on RT treated patients, Caucasian race is associated with higher CSM and OM rates relative to AA race; however, the effect of RT appears unrelated to race and virtually the same absolutes findings were recorded in Caucasian and AA patients.

**Competing interests:** Dr. Soulières has been an advisory board member for BMS, Merck, Novartis, and Pfizer; has received grants/honoraria from BMS, Merck, and Pfizer; and has participated in clinical trials supported by BMS, Merck, Novartis, and Pfizer. Dr. Saad has been an advisory board member for and has received grants/honoraria from Abbvie, Amgen, Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen, Astellas, Bayer, Janssen, and Sanofi. The remaining authors report no competing personal or financial interests related to this work.

This paper has been peer-reviewed.

**References**

1. Gnatzie C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: Data from the Munich cancer registry. *Eur Urol* 2014;66:4023. https://doi.org/10.1016/j.eururo.2014.04.009
2. Culp SH, Schaffhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumour? A SEER-based study. *Eur Urol* 2014;65:1058–66. https://doi.org/10.1016/j.eururo.2013.11.012
3. Antal S, Everson TM. Prognostic impact of definitive local therapy of the primary tumour in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis. *Cancer Epidemiol Biomarkers Prev* 2014;23:4354-61. https://doi.org/10.1158/1055-9965.EPI-14-0402
4. Fossa S, Trinh QD, Sammon J, et al. Identifying optimal candidates for focal treatment of the primary tumour among patients diagnosed with metastatic prostate cancer: A SEER-based study. *Eur Urol* 2015;67:34. https://doi.org/10.1016/j.eururo.2014.08.056

---

**Table 4. Multivariable Cox regression models* predicting CSM and OM in patients with newly diagnosed metastatic prostate cancer treated with brachytherapy**

| Variables          | CSM HR (95% CI) | p   | OM HR (95% CI) | p   |
|--------------------|-----------------|-----|----------------|-----|
| **Race**           |                 |     |                |     |
| AA                 | REF             |     | REF            |     |
| Caucasian          | 1.25 (0.62–2.50)| p=0.5| 1.12 (0.67–2.17)| p=0.5|
| PSA                |                 |     |                |     |
| <50                | 0.42 (0.13–1.35)| p=0.35| 0.35 (0.12–0.99)| p=0.049|
| 50–98              | REF             |     | REF            |     |
| >98                | 1.37 (0.41–4.52)| p=0.6 | 1.24 (0.43–3.59)| p=0.6 |
| **Gleason score (biopsy)** |       |     |                |     |
| ≤6                 | 0.28 (0.08–0.98)| p=0.048| 0.32 (0.12–0.85)| p=0.02|
| 7                  | REF             |     | REF            |     |
| 8–10               | 1.35 (0.62–2.93)| p=0.4 | 0.97 (0.51–1.86)| p=0.9 |
| Unknown            | 1.27 (0.53–3.01)| p=0.6 | 1.17 (0.57–2.39)| p=0.6 |
| **Clinical T stage** |                 |     |                |     |
| <T2                | REF             |     | REF            |     |
| T2                 | 0.62 (0.31–1.22)| p=0.2 | 0.74 (0.42–1.32)| p=0.3 |
| T3                 | 0.19 (0.03–0.91)| p=0.038| 0.48 (0.15–1.47)| p=0.2 |
| T4                 | 1.73 (0.68–4.37)| p=0.2 | 2.00 (0.88–4.54)| p=0.1 |
| **Clinical N stage** |                 |     |                |     |
| N0/NX              | REF             |     | REF            |     |
| N1                 | 1.16 (0.45–2.97)| p=0.7 | 1.84 (0.35–1.97)| p=0.7 |
| **AJCC M stage**   |                 |     |                |     |
| M1a                | REF             |     | REF            |     |
| M1b                | 2.51 (0.66–9.56)| p=0.1 | 2.36 (0.79–7.05)| p=0.1 |
| M1c                | 4.58 (1.12–18.6)| p=0.033| 3.64 (1.15–11.5)| p=0.02|
| Unknown            | 1.83 (0.16–20.6)| p=0.6 | 1.09 (0.11–10.9)| p=0.9 |

*Adjusted for age and marital status. AA: African American; AJCC: American Joint Committee on Cancer; CI: confidence interval; CSM: cancer-specific mortality; HR: hazard ratio; OM: overall mortality; PSA: prostate-specific antigen; REF: reference.
5. Löppenberg B, Dalova D, Kiseba P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: A national cancer database analysis. Eur Urol 2017;72:149. https://doi.org/10.1016/j.eururo.2016.04.031

6. Lehy-Barmohan SR, Gazdovich S, Budács L, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol 2017;72:118–24. https://doi.org/10.1016/j.eururo.2017.03.020

7. Gandaglio G, Fossati N, Stebile A, et al. Radical prostatectomy in men with oligometastatic prostate cancer: Results of a single-institution series with long-term followup. Eur Urol 2017;72:289–92. https://doi.org/10.1016/j.eururo.2016.08.040

8. Heidbrecher A, Pfister D, Pomes D. Cytoreductive radical prostatectomy in patients with prostate cancer and low-volume skeletal metastases: Results of a feasibility and case-control study. J Urol 2018;199:832–8. https://doi.org/10.1016/j.juro.2018.09.089

9. Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs. no local therapy for survival benefit in metastatic prostate cancer — a SEER-Medicare analysis. J Urol 2015;194:378–85.

10. Sattinshamaran P, Kames J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016;69:788–94. https://doi.org/10.1016/j.eururo.2015.05.023

11. NIH. Impact of radical prostatectomy as primary treatment in patients with prostate cancer with limited bone metastases (qBAMPP). Available at: https://clinicaltrials.gov/ct2/show/study/NCT02454543?term=NCT02454543&rank=1. Accessed March 25, 2019.

12. NIH. Best systemic therapy or best systemic therapy (BST) plus definitive treatment (radiation or surgery).

13. NIH. Impact of radical prostatectomy as primary treatment in patients with prostate cancer with limited bone metastases (qBAMPP). Available at: https://clinicaltrials.gov/ct2/show/study/NCT02454543?term=NCT02454543&rank=1. Accessed March 25, 2019.

14. Chornokur G, Dalton K, Borysova M, et al. Disparities at presentation, diagnosis, treatment, and survival in African American men affected by prostate cancer. Prostate 2017;77:1499–505. https://doi.org/10.1002/pros.23437

15. Chornokur G, Dalton K, Borysova M, et al. Disparities at presentation, diagnosis, treatment, and survival in African American men affected by prostate cancer. Prostate 2017;77:1499–505. https://doi.org/10.1002/pros.23437

16. Lindquist KI, Paris PL, Hoffmann TJ, et al. Mutational landscape of aggressive prostate tumours in African American men. Cancer Res 2016;76:1860–8. https://doi.org/10.1158/0008-5472.CAN-15-1787

17. Shina M, Hashimoto Y, Kato T, et al. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African Americans and Caucasians. Oncotarget 2017;8:8536–8. https://doi.org/10.18632/oncotarget.14198

18. Woods-Burnham L, Bau A, Caijas-Ors C, et al. The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models. Prostate 2018;77:1601–8. https://doi.org/10.1002/pros.23437

19. Freedland SJ, Vidal AC, Howard LE, et al. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer 2017;123:4199–4206. https://doi.org/10.1002/cncr.30834

20. Steele CB, Li J, Huang B, et al. Prostate cancer survival in the United States by race and stage (2001–2009): Findings from the CONCORD-2 study. Cancer 2017;123:5160–77. https://doi.org/10.1002/cncr.31026

21. Zeng C, Wen W, AK M, et al. Disparities by race, age, and sex in the improvement of survival for major cancers: Results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990–2010. JAMA Oncol 2015;1:88–96. https://doi.org/10.1001/jamaoncol.2014.161

22. Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results Program, 1973–2009: Findings from the CONCORD-2 study. Eur J Cancer Prev 2017;26:632–41. https://doi.org/10.1097/EP.0000000000000469

23. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Cancer 2010;116:2077–9. https://doi.org/10.1002/cncr.28584

24. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Am Surg Oncol 2010;17:1471–4. https://doi.org/10.1245/s10434-010-0985-4

Correspondence: Dr. Elio Mazzone, Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy; eliomazzone@gmail.com